- Home
- RNAC vs RIGL Comparison
RNAC vs RIGL Comparison
Compare RNAC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- RIGL
- Stock Information
- Founded
- RNAC 2007
- RIGL 1996
- Country
- RNAC United States
- RIGL United States
- Employees
- RNAC N/A
- RIGL N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- RIGL Health Care
- Exchange
- RNAC Nasdaq
- RIGL Nasdaq
- Market Cap
- RNAC 316.1M
- RIGL 335.5M
- IPO Year
- RNAC 2016
- RIGL 2000
- Fundamental
- Price
- RNAC $13.33
- RIGL $20.17
- Analyst Decision
- RNAC Strong Buy
- RIGL Buy
- Analyst Count
- RNAC 5
- RIGL 5
- Target Price
- RNAC $40.00
- RIGL $36.40
- AVG Volume (30 Days)
- RNAC 83.7K
- RIGL 206.2K
- Earning Date
- RNAC 08-07-2025
- RIGL 08-05-2025
- Dividend Yield
- RNAC N/A
- RIGL N/A
- EPS Growth
- RNAC N/A
- RIGL N/A
- EPS
- RNAC N/A
- RIGL 2.08
- Revenue
- RNAC $34,173,000.00
- RIGL $203,077,000.00
- Revenue This Year
- RNAC N/A
- RIGL $14.41
- Revenue Next Year
- RNAC N/A
- RIGL $15.97
- P/E Ratio
- RNAC N/A
- RIGL $9.71
- Revenue Growth
- RNAC 31.91
- RIGL 70.16
- 52 Week Low
- RNAC $8.46
- RIGL $8.61
- 52 Week High
- RNAC $26.50
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- RNAC 60.40
- RIGL 55.31
- Support Level
- RNAC $11.80
- RIGL $18.66
- Resistance Level
- RNAC $13.91
- RIGL $21.38
- Average True Range (ATR)
- RNAC 1.10
- RIGL 0.78
- MACD
- RNAC 0.03
- RIGL 0.19
- Stochastic Oscillator
- RNAC 53.04
- RIGL 61.46
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.